-
Something wrong with this record ?
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis
AG. Willison, R. Hagler, M. Weise, S. Elben, N. Huntemann, L. Masanneck, S. Pfeuffer, S. Lichtenberg, KS. Golombeck, LM. Preuth, L. Rolfes, M. Öztürk, T. Ruck, N. Melzer, M. Korsen, SL. Hauser, HP. Hartung, PA. Lang, M. Pawlitzki, S. Räuber, SG. Meuth
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
Project number: MOMB157A_FVSP002
Novartis Deutschland GmbH
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-03-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
40214505
DOI
10.3390/cells14070552
Knihovny.cz E-resources
- MeSH
- Antigens, CD20 * immunology MeSH
- B-Lymphocytes immunology drug effects MeSH
- Killer Cells, Natural immunology MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Multiple Sclerosis, Relapsing-Remitting * immunology drug therapy MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
INTRODUCTION: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding of disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS). A comprehensive analysis of the peripheral immune cell profile, combined with prospective clinical characterization, of RRMS patients treated with ocrelizumab (OCR) or ofatumumab (OFA) was performed to further understand immune reconstitution following B-cell depletion. METHODS: REBELLION-MS is a longitudinal analysis of RRMS patients treated with either OCR (n = 34) or OFA (n = 25). Analysis of B, T, natural killer (NK) and natural killer T (NKT) cells at baseline, month 1, and 12 was performed by multidimensional flow cytometry. Data were analyzed by conventional gating and unsupervised computational approaches. In parallel, different clinical parameters were longitudinally assessed. Twenty treatment-naïve age/sex-matched RRMS patients were included as the control cohort. RESULTS: B-cell depletion by OCR and OFA resulted in significant reductions in CD20+ T and B cells as well as B-cell subsets, alongside an expansion of CD5+CD19+CD20- B cells, while also elevating exhaustion markers (CTLA-4, PD-1, TIGIT, TIM-3) across T, B, NK, and NKT cells. Additionally, regulatory T-cell (TREG) numbers increased, especially in OCR-treated patients, and reductions in double-negative (CD3+CD4-CD8-) T cells (DN T cells) were observed, with these DN T cells having higher CD20 expression compared to CD4 or CD8 positive T cells. These immune profile changes correlated with clinical parameters, suggesting pathophysiological relevance in RRMS. CONCLUSIONS: Our interim data add weight to the argumentation that the exhaustion/activation markers, notably TIGIT, may be relevant to the pathogenesis of MS. In addition, we identify a potentially interesting increase in the expression of CD5+ on B cells. Finally, we identified a population of double-negative T cells (KLRG1+HLADR+, in particular) that is associated with MS activity and decreased with CD20 depletion.
Brain and Mind Center University of Sydney Sydney NSW 2050 Australia
Department of Neurology Medical University of Vienna 1090 Vienna Austria
Department of Neurology Palacky University 771 46 Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016160
- 003
- CZ-PrNML
- 005
- 20250731091545.0
- 007
- ta
- 008
- 250708s2025 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cells14070552 $2 doi
- 035 __
- $a (PubMed)40214505
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Willison, Alice G $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000207198334
- 245 10
- $a Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis / $c AG. Willison, R. Hagler, M. Weise, S. Elben, N. Huntemann, L. Masanneck, S. Pfeuffer, S. Lichtenberg, KS. Golombeck, LM. Preuth, L. Rolfes, M. Öztürk, T. Ruck, N. Melzer, M. Korsen, SL. Hauser, HP. Hartung, PA. Lang, M. Pawlitzki, S. Räuber, SG. Meuth
- 520 9_
- $a INTRODUCTION: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding of disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS). A comprehensive analysis of the peripheral immune cell profile, combined with prospective clinical characterization, of RRMS patients treated with ocrelizumab (OCR) or ofatumumab (OFA) was performed to further understand immune reconstitution following B-cell depletion. METHODS: REBELLION-MS is a longitudinal analysis of RRMS patients treated with either OCR (n = 34) or OFA (n = 25). Analysis of B, T, natural killer (NK) and natural killer T (NKT) cells at baseline, month 1, and 12 was performed by multidimensional flow cytometry. Data were analyzed by conventional gating and unsupervised computational approaches. In parallel, different clinical parameters were longitudinally assessed. Twenty treatment-naïve age/sex-matched RRMS patients were included as the control cohort. RESULTS: B-cell depletion by OCR and OFA resulted in significant reductions in CD20+ T and B cells as well as B-cell subsets, alongside an expansion of CD5+CD19+CD20- B cells, while also elevating exhaustion markers (CTLA-4, PD-1, TIGIT, TIM-3) across T, B, NK, and NKT cells. Additionally, regulatory T-cell (TREG) numbers increased, especially in OCR-treated patients, and reductions in double-negative (CD3+CD4-CD8-) T cells (DN T cells) were observed, with these DN T cells having higher CD20 expression compared to CD4 or CD8 positive T cells. These immune profile changes correlated with clinical parameters, suggesting pathophysiological relevance in RRMS. CONCLUSIONS: Our interim data add weight to the argumentation that the exhaustion/activation markers, notably TIGIT, may be relevant to the pathogenesis of MS. In addition, we identify a potentially interesting increase in the expression of CD5+ on B cells. Finally, we identified a population of double-negative T cells (KLRG1+HLADR+, in particular) that is associated with MS activity and decreased with CD20 depletion.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a relabující-remitující roztroušená skleróza $x imunologie $x farmakoterapie $7 D020529
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a antigeny CD20 $x imunologie $7 D018951
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $x farmakologie $7 D061067
- 650 _2
- $a B-lymfocyty $x imunologie $x účinky léků $7 D001402
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a buňky NK $x imunologie $7 D007694
- 650 _2
- $a longitudinální studie $7 D008137
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hagler, Ramona $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Weise, Margit $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Elben, Saskia $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000242144550
- 700 1_
- $a Huntemann, Niklas $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000300158484
- 700 1_
- $a Masanneck, Lars $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000324961415
- 700 1_
- $a Pfeuffer, Steffen $u Department of Neurology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, 35392 Giessen, Germany
- 700 1_
- $a Lichtenberg, Stefanie $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $u Core Facility Flow Cytometry, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000347032571
- 700 1_
- $a Golombeck, Kristin S $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Preuth, Lara-Maria $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Rolfes, Leoni $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Öztürk, Menekse $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Ruck, Tobias $u Department of Neurology with Heimer Institute for Muscle Research, University Hospital Bergmannsheil, 44789 Bochum, Germany $1 https://orcid.org/0000000163328650
- 700 1_
- $a Melzer, Nico $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/000000022420701X
- 700 1_
- $a Korsen, Melanie $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Hauser, Stephen L $u UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA 94107, USA
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria $u Brain and Mind Center, University of Sydney, Sydney, NSW 2050, Australia $u Department of Neurology, Palacky University, 771 46 Olomouc, Czech Republic $1 https://orcid.org/0000000206146989 $7 nlk20050167624
- 700 1_
- $a Lang, Philipp A $u Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany
- 700 1_
- $a Pawlitzki, Marc $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Räuber, Saskia $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000189015572
- 700 1_
- $a Meuth, Sven G $u Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000325713501
- 773 0_
- $w MED00194911 $t Cells $x 2073-4409 $g Roč. 14, č. 7 (2025)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40214505 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091540 $b ABA008
- 999 __
- $a ok $b bmc $g 2366769 $s 1253285
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 14 $c 7 $e 20250406 $i 2073-4409 $m Cells $n Cells $x MED00194911
- GRA __
- $a Project number: MOMB157A_FVSP002 $p Novartis Deutschland GmbH
- LZP __
- $a Pubmed-20250708
